A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors

A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors

This phase 1 trial (NCT01938846) determined the maximum tolerated dose (MTD) of the mTOR serine/threonine kinase inhibitor, BI 860585, as monotherapy and with exemestane or paclitaxel in patients with advanced solid tumors. This 3+3 dose-escalation study assessed BI 860585 monotherapy (5–300 mg/day;...

Full description

Bibliographic Details
Main Authors: Filippo de Braud, Jean-Pascal H. Machiels, Daniela Boggiani, Sylvie W.H. Rottey, Matteo Duca, Marie Laruelle, Stefania Salvagni, Silvia Damian, Lore D.F. Lapeire, Marcello Tiseo, Alexandre Dermine, Mahmoud Ould-Kaci, Juergen Braunger, Juliane Rascher, Daniela Fischer, Josef Hoefler, Gabriella L. Mariani, Sara Cresta
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
mTOR serine-threonine kinases
BI 860585
clinical trial
phase 1
maximum tolerated dose
pharmacokinetics
Online Access:https://www.mdpi.com/2072-6694/12/6/1425

Internet

https://www.mdpi.com/2072-6694/12/6/1425

Similar Items